Trial record 1 of 1 for:
NCT04465890
A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04465890 |
|
Recruitment Status :
Active, not recruiting
First Posted : July 10, 2020
Last Update Posted : April 3, 2024
|
Sponsor:
Ascletis Pharmaceuticals Co., Ltd.
Collaborators:
Peking University First Hospital
Beijing Clinical Service Center
Information provided by (Responsible Party):
Ascletis Pharmaceuticals Co., Ltd.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | August 30, 2024 |
| Estimated Study Completion Date : | August 30, 2024 |